Daraxonrasib: Why Doctors Are Calling This Pancreatic Cancer Pill the Biggest Breakthrough in Decades

Pancreatic cancer has long been one of oncology’s bleakest diagnoses. Half of all patients die within three months, and once the disease spreads to other organs, only about 3 percent survive five years.

This week at the EORTC-NCI-AACR Symposium in Barcelona, researchers shared clinical trial results that have doctors using words they almost never use for advanced pancreatic cancer: “closest to cure.”

What the Trial Showed

In a study of 61 patients newly diagnosed with advanced, metastatic pancreatic cancer, a daily pill called daraxonrasib (marketed as Rasonque) produced unprecedented responses over a median follow-up of 18 months:

  • Tumors Halted or Shrunk: Tumors stopped growing in 90 percent of patients, and shrank or disappeared in just over 60 percent.
  • Undetectable Disease: In roughly 8 percent of patients—one in 12—tumors became completely undetectable on CT scans.
  • Major Survival Gain: One year after starting treatment, 76.6 percent of patients were still alive, compared with the typical 40 to 45 percent one-year survival rate seen with chemotherapy alone. In a separate frontline combination cohort with chemotherapy, the drug delivered 12.8 months of progression-free survival.

Cracking an “Undruggable” Target

For decades, the KRAS gene mutations that drive most pancreatic cancers were considered practically impossible to drug. Daraxonrasib works as a targeted KRAS inhibitor, locking onto and shutting down the mutant signaling that fuels tumor growth. Because similar KRAS mutations appear in dozens of other cancers, researchers are already hopeful the approach could extend far beyond the pancreas.

Hope Tempered With Scientific Caution

Dr. Wungki Park of Memorial Sloan Kettering Cancer Center, who presented the findings, noted he had never seen so many tumors vanish in patients whose cancer had already spread. At the same time, Cancer Research UK chief executive Michelle Mitchell and trial doctors emphasized that daraxonrasib cannot yet be called a cure—larger, longer studies are still needed to confirm lasting remission and secure broader health-system access, including future NHS evaluation.

Still, for patients and families facing one of medicine’s toughest battles, turning an “undruggable” target into a daily pill marks the most hopeful leap forward in decades.

Scroll to Top